Last updated: February 19, 2026
This report provides a detailed analysis of World Intellectual Property Organization (WIPO) patent application WO2009080651, focusing on its scope, claims, and the surrounding patent landscape. The application, filed by Glaxo Group Limited, concerns pharmaceutical compositions and methods for treating or preventing respiratory diseases, particularly asthma and chronic obstructive pulmonary disease (COPD). The core of the invention relates to a combination therapy comprising a long-acting beta2-agonist (LABA) and an inhaled corticosteroid (ICS).
What is the Core Invention Claimed in WO2009080651?
The central claim of WO2009080651 is directed to a pharmaceutical composition containing specific amounts of a LABA, specifically formoterol, and an ICS, fluticasone furoate. The application details specific combinations and methods of administration for treating respiratory conditions.
- Claim 1 (as representative): A pharmaceutical composition comprising:
- An effective amount of formoterol fumarate.
- An effective amount of fluticasone furoate.
- A pharmaceutically acceptable carrier.
- The composition is formulated for inhalation.
The application further specifies synergistic effects and therapeutic advantages offered by this combination, particularly in relation to improved lung function and reduced exacerbations compared to monotherapies or other combination regimens. The intended use is for the treatment or prevention of inflammatory diseases of the airways, including asthma and COPD.
What are the Key Components and Specifications within the Patent Application?
WO2009080651 outlines several key components and specifications critical to its claimed invention. These include the specific active pharmaceutical ingredients (APIs), their dosages, and the method of delivery.
- Active Pharmaceutical Ingredients (APIs):
- Long-Acting Beta2-Agonist (LABA): Formoterol fumarate is explicitly identified. The application references prior art related to LABAs but focuses on its inclusion within this specific combination.
- Inhaled Corticosteroid (ICS): Fluticasone furoate is the specified ICS. The application emphasizes the specific properties of fluticasone furoate, such as its high potency and favorable pharmacokinetic profile, making it suitable for combination with formoterol.
- Dosage Ranges: While specific fixed dosages are not always provided for every embodiment, the application describes effective amounts. For example, it may refer to typical dosages for formoterol fumarate (e.g., 6 mcg) and fluticasone furoate (e.g., 80 mcg, 160 mcg) as representative or exemplary. The concept of an "effective amount" is central, implying doses sufficient to achieve a therapeutic benefit.
- Pharmaceutical Carrier: The application specifies that the composition includes a pharmaceutically acceptable carrier suitable for inhalation. This can encompass various excipients and propellant systems, depending on the intended delivery device.
- Delivery Device: The invention is intrinsically linked to an inhalation device. The application contemplates various dry powder inhalers (DPIs) or metered-dose inhalers (MDIs) that can deliver the combined APIs to the lungs. Specific examples of devices or types of devices may be discussed to illustrate the application of the claimed composition.
- Therapeutic Indications:
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Other inflammatory airway diseases.
The application may also detail methods of use, such as a regimen for daily administration, and the specific clinical outcomes sought, like improvement in FEV1 (forced expiratory volume in one second) and reduction in symptom scores or exacerbation frequency.
What is the Patent Landscape Surrounding WO2009080651?
The patent landscape for combination therapies involving LABAs and ICSs for respiratory diseases is highly competitive and densely populated with patents. WO2009080651 is situated within this established field, with numerous prior art patents and subsequent filings influencing its prosecution and potential market exclusivity.
- Key Players: Major pharmaceutical companies involved in respiratory drug development, including GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, and Novartis, hold significant patent portfolios in this area. Glaxo Group Limited, the applicant of WO2009080651, is a dominant force in respiratory medicine.
- Prior Art Landscape:
- Early Combination Patents: Patents covering earlier generation LABA/ICS combinations (e.g., salmeterol/fluticasone propionate, formoterol/budesonide) established the foundational concept of such fixed-dose combinations. Examples include patents for Advair (salmeterol/fluticasone propionate) and Symbicort (budesonide/formoterol).
- Specific API Patents: Patents covering the individual APIs themselves (formoterol, fluticasone furoate) and their formulations are critical. Patents related to novel ICS like fluticasone furoate, which offers enhanced potency and lung deposition, are particularly relevant.
- Formulation and Device Patents: Patents protecting specific dry powder formulations, particle engineering technologies, and inhalation device designs are also part of the landscape. These patents can impact the ability to deliver the claimed combination effectively and uniquely.
- WO2009080651's Position: This application, filed in 2008 (priority date potentially earlier), represents an effort to secure intellectual property for a specific combination using newer generation APIs (fluticasone furoate) and potentially novel formulations or delivery advantages. Its prosecution would have been influenced by the existing patent thicket.
- Post-Application Landscape: Since its filing, numerous patents have been granted covering:
- Newer LABA/ICS combinations.
- Triple therapy combinations (LABA, ICS, LAMA - long-acting muscarinic antagonist).
- Specific dosing regimens and pulsatile delivery systems.
- Formulations with improved stability or lung deposition.
- Combination products with different APIs targeting distinct pathways in respiratory disease.
The prosecution history of WO2009080651 would involve navigating these prior art references. The claims would likely have been narrowed or refined to distinguish from existing patents, particularly those covering similar combinations or the individual components. The patentability would depend on demonstrating novelty, inventive step, and industrial applicability over the known prior art.
How Will the Scope and Claims of WO2009080651 Impact Market Exclusivity?
The scope and claims of WO2009080651, if granted as a patent, would define the period of market exclusivity for the specific formoterol fumarate and fluticasone furoate combination for inhalation.
- Claim Scope: The breadth of the claims is critical.
- Narrow Claims: Claims that are very specific to the exact amounts of the APIs, specific carriers, or particular inhalation devices would offer limited protection. Competitors could design around such patents by altering dosages, formulations, or delivery systems.
- Broad Claims: Claims that encompass a range of dosages for the APIs, various pharmaceutically acceptable carriers, and multiple types of inhalation devices would provide more robust market exclusivity. However, such broad claims are more vulnerable to prior art challenges during prosecution and invalidation proceedings post-grant.
- Dependent Claims: The application likely includes dependent claims that further limit the invention, providing fallback positions if the broader claims are found unpatentable. These might specify particular particle sizes, polymorphic forms of the APIs, or specific excipient ratios.
- Method of Use Claims: Claims directed to methods of treating specific diseases (e.g., "a method of treating asthma comprising administering a composition comprising..."). These are important for defining the therapeutic applications protected.
- Impact on Generics: If a strong patent is granted, it would prevent generic manufacturers from marketing a bioequivalent product containing the same combination of formoterol fumarate and fluticasone furoate for the claimed indications during the patent term. The patent term is typically 20 years from the filing date, but can be extended in some jurisdictions (e.g., via Patent Term Extension in the US) to compensate for regulatory delays.
- Impact on Competitor Products: The patent could prevent competitors from developing and marketing similar fixed-dose combination products without licensing the technology. This is especially true if the patent covers a "composition of matter" claim, which is generally stronger than a "method of use" claim.
- Patent Term: The effective date of the patent and its expiry date are crucial for commercial planning. For an application filed in 2008, the earliest potential expiry date would be around 2028, excluding any patent term extensions.
- Enforcement: The strength of the patent in terms of its validity and enforceability in key markets (e.g., US, Europe, Japan) will determine its actual market impact. Litigation to enforce such patents is common in the pharmaceutical industry.
The ultimate market exclusivity conferred by WO2009080651 depends on the claims as granted, their interpretation by courts, and the competitive landscape of existing and future intellectual property.
What are the Potential Challenges and Opportunities for Competitors?
The existence of a patent application like WO2009080651, and any granted patent derived from it, presents both challenges and opportunities for competitors in the respiratory drug market.
Challenges for Competitors:
- Freedom to Operate (FTO): Competitors seeking to develop or market a similar formoterol/fluticasone furoate combination must conduct thorough FTO analyses to ensure they are not infringing any granted patent claims. This involves detailed examination of patent claims and their scope.
- Design-Around Strategies: If patent claims are broad, competitors will need to invest significantly in developing alternative formulations, different dosage regimens, or combination products with different APIs to avoid infringement. This can be costly and time-consuming.
- Licensing: In cases where direct FTO is challenging, competitors may consider licensing the patent from the patent holder. However, this would involve royalty payments and can limit strategic flexibility.
- Patent Invalidation: Competitors may challenge the validity of granted claims in patent offices or courts based on prior art not considered during examination. Successful invalidation would remove the exclusivity barrier.
- Product Differentiation: Competitors may focus on developing entirely new therapeutic approaches or significantly differentiated products (e.g., triple therapies, biologics) that operate in different patent spaces.
Opportunities for Competitors:
- Gap Identification: Competitors can analyze the claims of WO2009080651 (and any granted patent) to identify potential gaps or limitations. This might involve focusing on specific patient sub-populations not covered, alternative delivery routes, or novel therapeutic mechanisms.
- Prior Art Development: Thorough investigation of the prior art existing before the priority date of WO2009080651 can reveal prior disclosures that might limit the scope or validity of the patent.
- Developing Alternative Combinations: The landscape of respiratory medicine is evolving. Competitors can focus on developing other LABA/ICS combinations using different APIs, or combinations involving other drug classes (e.g., LAMA, novel anti-inflammatories) that are not covered by the patent.
- Invention of Non-Infringing Formulations/Devices: If the patent's claims are strongly tied to specific formulations or devices, competitors might find opportunities by developing innovative formulations or delivery devices that are demonstrably distinct and non-infringing.
- Post-Patent Expiry Entry: Competitors can plan for market entry once the patent term expires. This requires developing bioequivalent generic versions and preparing regulatory submissions well in advance.
Understanding the precise scope and claims of WO2009080651 is the first step for any competitor to navigate this complex intellectual property environment.
What is the Status of WO2009080651?
WIPO patent applications, such as WO2009080651, are published applications and do not represent granted patents in themselves. They indicate an intention to seek patent protection in multiple countries through the Patent Cooperation Treaty (PCT) system. The status of such an application typically involves several stages:
- International Filing and Publication: The application was filed and published by WIPO, making its contents publicly accessible.
- National/Regional Phase Entry: Following the PCT international phase, the applicant must typically enter the "national phase" or "regional phase" in the specific countries or regions where patent protection is desired. This involves filing translations of the application, paying national fees, and responding to patent office objections.
- Examination: Once in the national/regional phase, each patent office (e.g., USPTO in the US, EPO in Europe, JPO in Japan) will examine the application based on its own patent laws and examination guidelines. This involves:
- Novelty and Inventive Step: Assessing whether the invention is new and non-obvious compared to prior art.
- Clarity and Sufficiency of Disclosure: Ensuring the application adequately describes the invention and its use.
- Patentability Requirements: Checking for compliance with all national patentability criteria.
- Grant or Rejection: The patent office will either grant the patent (with claims potentially amended during examination) or reject the application.
- Potential for Opposition/Revocation: Even after a patent is granted, it may be subject to opposition proceedings or revocation actions by third parties who believe it was wrongly granted.
Specific to WO2009080651:
To determine the current status of WO2009080651 and whether it has proceeded to grant in specific jurisdictions, a detailed search of national and regional patent databases is required. WIPO's Patentscope database provides access to international applications and their status updates. However, the ultimate grant decision and the specific claims of granted patents will be found in the national/regional patent offices where the applicant pursued protection. As of the knowledge cutoff, WO2009080651 is an international publication, and its granted status in any particular country would be determined by the prosecution at that national/regional patent office.
Key Takeaways
- WIPO patent application WO2009080651 claims a pharmaceutical composition for treating respiratory diseases, comprising formoterol fumarate (LABA) and fluticasone furoate (ICS) for inhalation.
- The core invention focuses on the synergistic therapeutic benefits of this specific LABA/ICS combination.
- The patent landscape for respiratory combination therapies is dense, with significant prior art concerning LABA/ICS combinations and individual API patents.
- Market exclusivity derived from a granted patent would prevent generic competition for the specific combination and indications.
- Competitors face challenges in freedom to operate and may need to pursue design-around strategies, licensing, or patent invalidation.
- Opportunities exist for competitors through gap identification, developing alternative combinations, or creating non-infringing formulations and devices.
- WO2009080651 is an international publication; its patentability and granted status depend on national/regional patent office examinations.
FAQs
-
What specific diseases are targeted by the invention claimed in WO2009080651?
The application primarily targets inflammatory diseases of the airways, specifically asthma and chronic obstructive pulmonary disease (COPD).
-
Are there any specific dosage amounts mentioned for formoterol fumarate and fluticasone furoate in WO2009080651?
The application refers to "effective amounts" and may provide exemplary or typical dosage ranges for the components, such as 6 mcg for formoterol fumarate and 80 mcg or 160 mcg for fluticasone furoate, depending on the specific embodiment described.
-
Does WIPO patent application WO2009080651 represent a granted patent?
No, WIPO patent applications are published international applications and do not inherently represent granted patents. The applicant must pursue national or regional phase entry in individual countries for examination and potential grant.
-
What is the primary advantage of combining formoterol fumarate and fluticasone furoate as described in WO2009080651?
The primary advantage described is the synergistic therapeutic effect of combining a LABA with an ICS, leading to improved lung function and reduced exacerbations compared to monotherapies.
-
How can a competitor assess their freedom to operate concerning the technology described in WO2009080651?
A competitor must conduct a Freedom to Operate (FTO) analysis, which involves searching patent databases for granted patents derived from WO2009080651 in relevant jurisdictions and carefully analyzing their claims to determine if a proposed product or process would infringe.
Citations
[1] Glaxo Group Limited. (2009). Pharmaceutical compositions and methods for treating respiratory diseases. World Intellectual Property Organization. (WO2009080651 A1).
